OneMedNet uzavřel dvanáctou partnerskou distribuční dohodu; globální poskytovatel farmaceutických dat bude deidentifikovaná klinická data společnosti z USA nabízet farmaceutickým zákazníkům po celém světě.
MINNEAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced its 12th channel partner agreement, under which a leading global provider of pharmaceutical intelligence and data solutions will distribute OneMedNet’s U.S.-sourced, de-identified clinical data to its established base of pharmaceutical customers worldwide. The agreement broadens OneMedNet’s reach into one of the fastest-growing segments of life sciences data. The global Real-World Data market is estimated at approximately US$2.7 billion in 2026 and is projected to reach US$7.1 billion by 2033, according to Coherent Market Insights1, as pharmaceutical companies increasingly rely on Real-World Data to support drug development, regulatory submissions, and commercial decisions.
OneMedNet is witnessing data partners increasingly select its Real-World Data for the qualities pharmaceutical customers value most: first-party data sourced directly from healthcare providers rather than intermediaries or secondary markets, de-identified at the source, and delivered at regulatory-grade quality. By pairing OneMedNet’s multimodal clinical data with their own analytics and intelligence offerings, partners can support their pharmaceutical customers across clinical development, regulatory submissions, market access, and medical AI.
This agreement marks OneMedNet’s 12th channel partnership, reflecting a deliberate strategy to extend the Company’s commercial reach through established distribution channels while maintaining direct control of data sourcing, curation, and de-identification.
“We believe our channel partners choose OneMedNet for the same reason end customers do: data that comes straight from the source,” said Aaron Green, President & CEO of OneMedNet. “First-party, direct-from-source data gives our partners confidence in the quality, provenance, and compliance of what they deliver to their customers. This partnership expands our reach in the pharmaceutical market.”
About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.
Learn more at www.onemednet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the benefits and expected scope of the channel partner agreement, our distribution strategy, and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
MINNEAPOLIS, Oct. 15, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced the addition of a leading hospital system to its iRWD™ platform and federated provider network and expects to expand the network by up to 12 additional hospitals. The new partnership meaningfully expands both the scale and more importantly clinical depth of OneMedNet’s healthcare data network.
This expansion provides first party, direct-from-source delivering multimodal medical imaging, rich clinical reports, and associated healthcare data spanning the full continuum of care across all therapy areas. By capturing complete patient journeys over time—from initial diagnosis through treatment and follow-up—OneMedNet continues to build the longitudinal depth that AI developers, life sciences companies, and medical device innovators require.
“Every expansion of our network strengthens what we believe is OneMedNet’s core differentiator: the depth and completeness of our longitudinal patient data, delivered as fully de-identified, regulatory-grade datasets through our secure federated network of live source data,” said Aaron Green, CEO & President of OneMedNet. “Direct-from-source environments give us a quality and richness of data that aggregated sources can’t replicate. We believe that depth is what fuels meaningful AI innovation and robust Real-World Evidence at the speed, scale, and quality modern healthcare demands and it continues to expand our pipeline as we build OneMedNet’s position as a preferred provider of regulatory-grade datasets.”
The expanded network is expected to directly support OneMedNet’s role in advancing healthcare innovation on two fronts. First, the Company’s regulatory-grade, AI-ready data fuels AI innovation, including the development, training, and validation of foundational AI models and clinical algorithms that depend on high-quality, diverse, and deeply annotated healthcare data building on the Company’s recently announced agreement to supply data for foundational AI model development. Second, the Company’s longitudinal Real-World Data enables the generation of Real-World Evidence (RWE) that supports regulatory submissions, post-market surveillance, clinical research, and market access decisions across the life sciences and medical device industries.
About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.
Learn more at www.onemednet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our recent partnership with the announced hospital system, including its benefits and affects on our network, and the general demand for our products, our ability to achieve our operational strategies, our expected growth in the business and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet uzavřel svou 11. partnerskou dohodu se společností Mediplexus, která bude v Koreji distribuovat zdravotnická data společnosti z USA a rozšíří její dosah v asijsko-pacifickém regionu.
MINNEAPOLIS, Oct. 07, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real World Data (RWD), today announced its 11th channel partner agreement with Mediplexus, a healthcare data company specializing in RWD and Real World Evidence (RWE) and a subsidiary of C&R Research, one of Korea’s leading contract research organizations (CROs). Under the agreement, OneMedNet will supply its U.S.-sourced Real World Data to Mediplexus, its appointed distributor in Korea – extending OneMedNet’s commercial reach into the broader Asia Pacific region. The companies plan to broaden the scope of the collaboration in stages following an initial one-year engagement.
Through the agreement, Mediplexus will offer OneMedNet’s U.S sourced healthcare data alongside its own Korean healthcare data, each delivered in a form tailored to the customer’s purpose — significantly widening the field on which Korean biopharma, medtech and medical AI companies can pursue global clinical trials, RWD and RWE research, drug development, and medical AI initiatives. Mediplexus plans to pair OneMedNet’s data with analysis, model validation, and regulatory and market-access support to help Korean medical device and medical AI companies enter the U.S. market.
OneMedNet’s iRWD™ network — now exceeding 90 million patient journeys, 270 million studies, and more than 2,300 healthcare partner sites — delivers multimodal data spanning radiology, cardiology, EEG, and ECG, together with de-identified electronic health records. The data is sourced directly from healthcare providers, not intermediaries or secondary markets, and de-identified at the source.
The agreement comes as the global regulatory environment increasingly moves toward formal acceptance of RWD and RWE. Both the U.S. FDA and the European EMA encourage the use of RWE, and following the adoption of the ICH M14 guideline1 in 2025, the global RWE solutions market is projected to grow from USD 5.4 billion in 2025 to USD 10.8 billion by 20302.
“Asia Pacific is expected to register the fastest growth in the RWE solutions market, driven by expanding healthcare data infrastructure2” said Aaron Green, President & CEO of OneMedNet. “This agreement puts our first-party, direct-from-source multimodal data into the hands of a partner with deep clinical research roots in the region. Mediplexus and C&R Research bring the local expertise, relationships, and regulatory know-how to make our data actionable for Korean innovators and this initial engagement is structured to expand in both scope and geography over time.”
About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.
Learn more at www.onemednet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the planned expansion to the Asia Pacific market and related expectations, projected market growth, and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet uzavřel sedmimístnou víceletou dohodu na dodávky deidentifikovaných klinických dat pro AI firmu zaměřenou na přesnou medicínu. Součástí je i možnost opakovaných sublicenčních příjmů z odvozeného datasetu.
MINNEAPOLIS, Sept. 30, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real World Data (RWD), today announced a seven figure multiyear agreement to deliver de-identified, multimodal, longitudinal clinical Real World Data to a commercially scaled AI-enabled precision medicine company.
The data will be delivered to the customer through OneMedNet’s iRWD™ Platform. The customer intends to use the data to train AI-enabled clinical and diagnostic models and to create a licensable derivative dataset to sell into its own channel, linking the customer’s molecular datasets with OneMedNet’s first-party imaging and longitudinal clinical journeys. Combined, the derived product is designed to be more valuable and more actionable for life-sciences customer base than either source alone.
OneMedNet earns incremental annual sublicensing revenue each time that our solution is licensed to the customer’s end user in addition to the initial data license. The agreement includes an option to expand data volume and contract value.
The customer is a developer of AI-enabled precision medicine products with a well-established customer base in the life sciences. It selected OneMedNet’s first-party data sourced directly from a live network of more than 2,300 healthcare partner sites, not intermediaries or secondary markets. OneMedNet solutions applies de-identification at the source, at the scale and standards to enable AI training of evolving foundation models and to satisfy other life science commercial data needs.
"Sophisticated AI companies in healthcare are not buying one-time data pulls. They want a long-term source of multimodal, regulatory-grade data, direct from the source, at the quality required to build models and commercialize their data products," said Aaron Green, President & CEO of OneMedNet. "That is this agreement: a seven figure multiyear license, plus a derivative dataset our partner will commercialize, with OneMedNet paid on every downstream license — multiyear licenses, sublicensing on solutions built with our data, and room to expand."
Agreement highlights
Seven-figure, multiyear agreement, with an option to expand volume and value.Customer-sold derivative dataset with OneMedNet’s tenth channel partner, and recurring sublicensing revenue to OneMedNet on each end-customer license.First-party, direct-from-source data, de-identified at the source, from more than 2,300 partner sites.OneMedNet retains source-data rights. End customers of the derivative may not relicense or resell the underlying OneMedNet data. About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.
Learn more at www.onemednet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to statements regarding the benefits and capabilities of our products and the customer agreement, and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
MINNEAPOLIS, Sept. 25, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “Company,” “we,” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced that it will implement a 1-for-10 reverse stock split of its issued and outstanding shares of common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern Time on September 29, 2026. The Reverse Stock Split was approved by the Company’s stockholders at its Annual Meeting of Stockholders held on September 18, 2026, with the final ratio, within the range approved by stockholders, subsequently determined by the Company’s board of directors. The Reverse Stock Split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, and to broaden investor interest.
The Company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on September 29, 2026 under the Company’s existing trading symbol “ONMD” with the new CUSIP number 68270C 202.
At the effective time of the Reverse Stock Split, every ten (10) shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock without any change in the par value per share. The Reverse Split will reduce the number of shares of outstanding common stock from approximately 59,286,450 shares, the number of shares outstanding as of September 24, 2026, to approximately 5,928,645 shares of common stock. The total authorized number of shares will not be reduced. The Reverse Stock Split will also proportionately adjust the number of shares available under the Company’s equity incentive plans and the exercise price and number of shares underlying outstanding restricted stock units, warrants, and other equity instruments, in each case in accordance with their terms.
No fractional shares will be issued in connection with the Reverse Stock Split. Any fractional shares of common stock resulting from the Reverse Stock Split will be rounded up to the nearest whole share. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s relative interest in the Company’s equity securities, except for any adjustments for fractional shares.
Continental Stock Transfer & Trust Company is acting as the exchange agent and transfer agent for the Reverse Stock Split. Stockholders holding their shares electronically are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker or other nominee will have their positions adjusted to reflect the Reverse Stock Split, subject to such broker's particular processes.
About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform is powered by Palantir Foundry and supports applications ranging from drug development and regulatory submissions to foundational AI model training.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements may describe our future plans and expectations and are based on the current beliefs, expectations and assumptions of the Company. These statements generally use terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or similar terms. Examples of forward-looking statements in this press release include but are not limited to statements about the timing and implementation of the Reverse Stock Split and the commencement of trading of the Company’s post-split common stock, the impact of the Reverse Stock Split on the Company’s securityholders, the potential for the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market and the expected number of shares of common stock to be issued and outstanding following the Reverse Stock Split.
We urge you to consider those factors, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “SEC”), any subsequently filed quarterly reports on Form 10-Q as well as in other documents that may have been subsequently filed by the Company, from time to time, with the SEC, in evaluating our forward-looking statements. In addition, any forward-looking statements represent the Company’ views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company does not assume any obligation to update any forward-looking statements unless required by law.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
SOURCE: ONEMEDNET CORPORATION
OneMedNet oznámil růst objednávek na zhruba 16,2 milionu USD za letošní rok, tedy 16násobek oproti stejnému období loňského roku. Fulfillment je navíc asi 50krát rychlejší.
MINNEAPOLIS, Sept. 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced year-to-date bookings of approximately $16.2 million, a 16X increase versus the same period in 2025. A significant portion of these bookings are expected to be delivered during the remainder of the year.
Approximately 50% of the contracts booked during 2026 are with new customers to OneMedNet, while the existing customer base continues to expand their business with the Company through high rates of reorder and follow-on engagement.
Platform improvements have increased OneMedNet’s order-fulfillment speed by approximately 50X, accelerating how quickly the Company can assemble, qualify, and deliver fit-for-purpose multi-modal datasets. This increase in speed allows the Company to take on large orders while providing quick delivery to meet our customers' project schedules.
Life sciences, medical device, and AI organizations continue to use OneMedNet’s iRWD™ Platform for regulatory submissions, foundation-model development, cohort discovery, feasibility studies, and high-value research, which is reflected in our bookings backlog. This builds on our network of more than 2,300 healthcare partner sites and more than 90 million patient journeys and 270 million studies.
Key Highlights
Contracted demand: Approximately $16.2 million in year-to-date bookings, a 16X increase over the same period in 2025.Growth from new and existing customers: Approximately 50% of contracts booked during 2026 are with new customers to OneMedNet, complemented by reorder and expansion activity from existing customers.Faster fulfillment: Order fulfillment is approximately 50X faster, which allows the Company to take on larger orders and deliver faster.
“Our commercial engine is delivering,” said Aaron Green, CEO & President. “Bookings are up more than 16X year over year, and we are executing to our contracted delivery schedules. Expanding demand combined with disciplined execution is what builds durable value. The market is shifting decisively towards direct-from-source, regulatory grade Real-World Data, and OneMedNet through our provider network and advanced technology is positioned to deliver it at the speed, scale, and quality that modern healthcare innovation demands.”
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the potential of more than 2,300 healthcare sites through its iRWD™ platform. This is not just data — it is the foundation of innovation, from de-identified medical imaging to electronic health records, fueling work for drugmakers, medical device companies, and AI developers. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that support patient care and the next wave of healthcare innovation.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding demand for our products and services, the composition and durability of our customer base, the speed of order fulfillment, the acceptance of our delivered data sets allowing for the conversion of bookings to revenue, our ability to achieve our operational strategies, our expected growth in the business, and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
OneMedNet uzavřel dohodu o dodávce deidentifikovaných klinických Real-World Data pro firmu zaměřenou na vývoj léčiv s využitím AI. Feasibility trvala minuty, validace dat týden a kontrakt byl podepsán do tří týdnů od prvního kontaktu.
MINNEAPOLIS, Aug. 31, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced a new agreement to deliver de-identified, full-fidelity clinical Real-World Data to a leading AI-driven drug development company. OneMedNet's iRWD™ Platform enabled cohort feasibility within minutes, data validation within a week, and signed contract within three weeks of initial contact, and is now delivering the data to support the customer's development and validation of AI models designed to accelerate and improve how new therapies are discovered and developed.
The customer selected OneMedNet after recognizing that building AI models capable of genuine innovation in drug development requires full-fidelity clinical studies at a level of quality that only data directly sourced from healthcare providers can deliver. OneMedNet’s network provides that fidelity at scale, with the curation, de-identification, and clinical integrity standards required for AI model training and validation.
“Healthcare innovators are coming to OneMedNet because they see what it takes to build AI that performs in the real world: private clinical data sourced directly from healthcare providers,” said Aaron Green, President & CEO of OneMedNet. “OneMednet provided first-party data is what enables our customers to accelerate the development and validation of their AI models, and we believe the surge in demand we are experiencing reflects it. Our iRWD platform enables this pace — feasibility, validation, contracting, and delivery in a matter of weeks — and the ease of doing business customers can expect.”
The agreement underscores the growing role of OneMedNet’s iRWD™ network — now exceeding 90 million patient journeys, 270 million studies, and more than 2,300 healthcare partner sites — as foundational infrastructure for AI model development across the healthcare and life sciences ecosystem. OneMedNet’s multimodal data spans Radiology, Cardiology, EEG, ECG, and other diagnostic modalities, alongside de-identified electronic health records, with optional tokenized linkage for longitudinally connected, multimodal datasets.
Agreement highlights:
Project feasibility completed within minutes.First-party, direct-from-source data delivered from a live network of Healthcare Provider partner sites.Regulatory decision-grade quality spanning de-identified medical imaging and comprehensive clinical records, suitable for AI model development and downstream regulatory use.Continued commercial momentum reflecting surging demand for private healthcare clinical data sourced directly from healthcare providers. About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform is powered by Palantir Foundry and supports applications ranging from drug development and regulatory submissions to foundational AI model training. Learn more at www.onemednet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the ability and benefits of our iRWD platform and the demand for our products, our ability to achieve our operational strategies, and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet uzavřel smlouvu na dodávku regulačně schválených zdravotnických dat pro vývoj a trénink základního modelu AI. Počáteční hodnota kontraktu přesahuje 11,5 milionu USD.
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced it has entered into an agreement to supply its regulatory-grade, multi-modal imaging-centric iRWD™ platform data for use in the development and training of a foundational AI model.
Under the terms of the agreement, OneMedNet will provide high-quality, de-identified, regulatory-grade healthcare data, including millions of medical imaging and associated clinical reports, with data delivery immediately. The initial agreement has a total contract value in excess of $11.5 million.
"We believe this agreement represents a significant validation of OneMedNet's unique capabilities in curating and delivering regulatory decision-grade Real-World Data at the scale and quality required for foundational AI model development. OneMedNet is uniquely positioned to deliver fully de-identified, regulatory-grade datasets through our secure, anonymized federated network of live data, enabling breakthrough AI innovation while upholding the highest standards of patient privacy and compliance. Our AI-powered iRWD™ platform, combined with our expansive provider network, makes this possible at the speed, scale, and quality that modern healthcare demands,” said Aaron Green, CEO & President of OneMedNet.
"Private data is what we believe will ultimately differentiate one foundational model from another—and healthcare data is among the most private and valuable. OneMedNet's delivery platform provides live, longitudinal access to this data, with in-flight anonymization built in," stated Jeffrey Yu, MD, Chairman of OneMedNet.”
This agreement is expected to build on OneMedNet’s strong commercial momentum and expanding network, which now surpasses 90 million patient journeys and 270 million clinical studies across more than 2,300 healthcare sites. This network continues to expand in scope and depth. The Company’s iRWD™ platform, enables secure, scalable delivery of multi-modal data optimized for AI training, regulatory submissions, and advanced analytics.
About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform is powered by Palantir Foundry and supports applications ranging from drug development and regulatory submissions to foundational AI model training. Learn more at www.onemednet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our ability to convert bookings into revenue and the demand for our products, our ability to achieve our operational strategies, our expected growth in the business and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
